Paper33799685
Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Carnevale-Schianca F and 26 others. J Clin Med, 2021. Cited by 17 papers, by iCite.
Cite this record
ConductScience Library. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. Papers, record 33799685. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33799685
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Ricerca DS-321 | FPRC ONLUS-5x1000 ,Ministero della Salute 2015 | PubMed | ||
| ADISCO Sezione Piemonte | ADISCO Sezione Piemonte | PubMed |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02300571 | Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant | Derived from the trial | Yes |
Source ClinicalTrials.gov
References62
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28249141 | Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28249141 | PubMed |
| 2 | 25667989 | Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. | Biol Blood Marrow Transplant | 2015 | https://conductscience.org/library/papers/25667989 | PubMed |
| 3 | 23478054 | Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23478054 | PubMed |
| 4 | 29567707 | CAR T cell immunotherapy for human cancer. | Science | 2018 | https://conductscience.org/library/papers/29567707 | PubMed |
| 5 | 26723083 | Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. | Lancet Oncol | 2016 | https://conductscience.org/library/papers/26723083 | PubMed |
| 6 | 28039079 | Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. | Biol Blood Marrow Transplant | 2017 | https://conductscience.org/library/papers/28039079 | PubMed |
| 7 | 29385370 | Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29385370 | PubMed |
| 8 | 20124511 | High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. | Blood | 2010 | https://conductscience.org/library/papers/20124511 | PubMed |
| 9 | 24958183 | Current and emerging strategies for the prevention of graft-versus-host disease. | Nat Rev Clin Oncol | 2014 | https://conductscience.org/library/papers/24958183 | PubMed |
| 10 | 25316679 | Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. | Blood | 2014 | https://conductscience.org/library/papers/25316679 | PubMed |
| 11 | 26970381 | Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil. | Biol Blood Marrow Transplant | 2016 | https://conductscience.org/library/papers/26970381 | PubMed |
| 12 | 27870568 | Morbidity and Mortality Differences Between Hematopoietic Cell Transplantation Survivors and Other Cancer Survivors. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/27870568 | PubMed |
| 13 | 23200544 | Have we made progress in the treatment of GVHD? | Best Pract Res Clin Haematol | 2012 | https://conductscience.org/library/papers/23200544 | PubMed |
| 14 | 30709437 | Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. | Lancet Haematol | 2019 | https://conductscience.org/library/papers/30709437 | PubMed |
| 15 | 19695955 | Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. | Lancet Oncol | 2009 | https://conductscience.org/library/papers/19695955 | PubMed |
| 16 | 21464398 | Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/21464398 | PubMed |
| 17 | 25682602 | Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial. | Haematologica | 2015 | https://conductscience.org/library/papers/25682602 | PubMed |
| 18 | 16338616 | National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. | Biol Blood Marrow Transplant | 2005 | https://conductscience.org/library/papers/16338616 | PubMed |
| 19 | 29040031 | Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/29040031 | PubMed |
| 20 | 32227211 | Late infectious complications in hematopoietic cell transplantation survivors: a population-based study. | Blood Adv | 2020 | https://conductscience.org/library/papers/32227211 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41114809 | Transplantation strategy affects the risk of GvHD after prophylactic and preemptive donor lymphocyte infusion. | Ann Hematol | 2025 | https://conductscience.org/library/papers/41114809 | PubMed |
| 40141738 | Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis After Peripheral Blood Stem Cell HLA Identical Transplantation in Patients with Lymphoma: A Prospective Observational Study. | Life (Basel) | 2025 | https://conductscience.org/library/papers/40141738 | PubMed |
| 39257713 | Comparison of Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis after "Allogeneic Stem Cell Transplantation from 9/10 HLA Matched Unrelated Donor'' with Standard Graft Versus Host Disease Prophylaxis after "10/10 HLA Matched Relative Donor'' Transplant. | Int J Hematol Oncol Stem Cell Res | 2024 | https://conductscience.org/library/papers/39257713 | PubMed |
| 38930096 | Optimizing Outcomes in Mismatched Unrelated Donor Allogeneic Transplantation: Post-Transplant Cyclophosphamide's Dual Impact on Graft versus Host Disease Incidence and Overall Survival: Retrospective Analysis on Behalf of Polish Adult Leukemia Group. | J Clin Med | 2024 | https://conductscience.org/library/papers/38930096 | PubMed |
| 38615143 | Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. | Bone Marrow Transplant | 2024 | https://conductscience.org/library/papers/38615143 | PubMed |
| 38545096 | Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation. | Front Immunol | 2024 | https://conductscience.org/library/papers/38545096 | PubMed |
| 37261557 | Posttransplant cyclophosphamide beyond haploidentical transplantation. | Ann Hematol | 2024 | https://conductscience.org/library/papers/37261557 | PubMed |
| 37140099 | Post-transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced-intensity conditioning allotransplant. | Clin Transl Med | 2023 | https://conductscience.org/library/papers/37140099 | PubMed |
| 35930118 | Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide. | Int J Hematol | 2022 | https://conductscience.org/library/papers/35930118 | PubMed |
| 35066570 | Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants. | Bone Marrow Transplant | 2022 | https://conductscience.org/library/papers/35066570 | PubMed |
| 34586587 | A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation. | Int J Hematol | 2022 | https://conductscience.org/library/papers/34586587 | PubMed |
| 34425261 | Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide. | Transplant Cell Ther | 2021 | https://conductscience.org/library/papers/34425261 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD34 | 947 | PubTator's text mining | https://conductscience.org/library/genes/947 | NCBI Gene |
| HLA-A | 3105 | PubTator's text mining | https://conductscience.org/library/genes/3105 | NCBI Gene |
| HLA-DQB1 | 3119 | PubTator's text mining | https://conductscience.org/library/genes/3119 | NCBI Gene |
| HLA-DRB1 | 3123 | PubTator's text mining | https://conductscience.org/library/genes/3123 | NCBI Gene |
| KRT20 | 54474 | PubTator's text mining | https://conductscience.org/library/genes/54474 | NCBI Gene |
| NR1I3 | 9970 | PubTator's text mining | https://conductscience.org/library/genes/9970 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33799685
GET https://conductscience.org/api/papers/v1/33799685/authors?page=2